A COOPERATIVE RANDOMIZED STUDY ON TEGAFUR PLUS MITOMYCIN-C VERSUS COMBINED TEGAFUR AND URACIL PLUS MITOMYCIN-C IN THE TREATMENT OF ADVANCED GASTRIC-CANCER

被引：42

作者：

KURIHARA, M

IZUMI, T

YOSHIDA, S

OHKUBO, T

SUGA, S

KIYOHASHI, A

YAOSAKA, T

TAKAHASHI, H

ITO, T

SASAI, T

AKIYA, T

AKAZAWA, S

BETSUYAKU, T

TAGUCHI, S

机构：

[1] NATL CANC CTR,DEPT INTERNAL MED,CHUO KU,TOKYO 104,JAPAN

[2] HIRAGA HOSP,DEPT INTERNAL MED 1,YOKOTE 013,JAPAN

[3] NAGOYA NATL HOSP,DEPT GASTROENTEROL,NAKA KU,NAGOYA 460,JAPAN

[4] KITAZATO UNIV,DEPT INTERNAL MED,SAGAMIHARA 228,JAPAN

[5] SAPPORO KOSEI HOSP,DEPT GASTROENTEROL,CHUO KU,SAPPORO 060,JAPAN

[6] TOHOKU UNIV,TB & CANC RES INST,DEPT CLIN CANC CHEMOTHERAPY,AOBA KU,SENDAI,MIYAGI 980,JAPAN

[7] JUNTENDO UNIV,DEPT INTERNAL MED,BUNKYO KU,TOKYO 113,JAPAN

[8] NATL OKAYAMA HOSP,DEPT INTERNAL MED,OKAYAMA 700,JAPAN

[9] TOHMO HOSP,GUNMA CANC CTR,DEPT INTERNAL MED,OHTA 373,JAPAN

[10] SAITAMA CANC CTR HOSP,DEPT GASTROENTEROL,INA 362,JAPAN

[11] NATL SAPPORO HOSP,DEPT GASTROENTEROL,SHIROISHI KU,SAPPORO 003,JAPAN

[12] SHOWA UNIV,DEPT INTERNAL MED 2,SHINAGAWA KU,TOKYO 142,JAPAN

来源：

JAPANESE JOURNAL OF CANCER RESEARCH | 1991年 / 82卷 / 05期

关键词：

RANDOMIZED STUDY; TEGAFUR; TEGAFUR AND URACIL; MMC; GASTRIC CANCER;

D O I：

10.1111/j.1349-7006.1991.tb01894.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A randomized controlled trial involving 13 institutions in Japan was conducted in order to compare the efficacy of tegafur plus mitomycin C (MMC) (Regimen A) and UFT (a combination of uracil and tegafur at a molar ratio of 4 to 1) plus MMC (Regimen B) for patients with advanced gastric cancer, who had not received any prior cancer chemotherapy. Regimen A (tegafur + MMC) consisted of 5 mg of MMC/m2/week given intravenously, and 500 mg of tegafur/m2/day given orally. Regimen B consisted of the same schedule of MMC and 375 mg of UFT/m2/day given orally. One hundred and eighty-six patients with primary gastric cancer were entered; 183 were eligible and 3 were ineligible for the study. A total of 169 were evaluable for efficacy of the treatment, including 90 patients with Regimen A and 79 with Regimen B. A response rate of 7.8% (7/90 cases) for Regimen A and one of 25.3% (20/79 cases) for Regimen B were obtained, indicating a significantly higher response rate for Regimen B according to the Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer (P = 0.004). Regarding side effects, no marked differences in either severity or incidence were observed between the two groups. The group assigned to Regimen B showed a significant survival advantage after adjustment for major prognostic factors using a proportional hazards model (P = 0.0398). Moreover, a close correlation of antitumor effect and survival duration was found when the above criteria were used.

引用

页码：613 / 620

页数：8

共 23 条

[1] ARBUCK SG, 1990, CANCER, V65, P2442, DOI 10.1002/1097-0142(19900601)65:11<2442::AID-CNCR2820651106>3.0.CO
[2] 2-7
[3] COX DR, 1972, J R STAT SOC B, V34, P187
[4] FUJII S, 1978, GANN, V69, P763
[5] FUJII S, 1979, GANN, V70, P209
[6] GOTO Y, 1989, JPN J CANC CHEMOTHER, V16, P2227
[7] Kimura K, 1967, Naika, V19, P1314
[8] KURIHARA M, 1981, CHEMOTHERAPY GASTRIC, P85
[9] KURIHARA M, 1980, JPN J CANCER CLIN, V26, P652
[10] KURIHARA M, 1981, DIAGNOSIS TREATMENT, P428

← 1 2 3 →